Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms

Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 —

Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last

Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery,

Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit

ACOU085, the lead candidate from Acousia Therapeutics, has been administered to the first patient with age-related hearing loss (presbycusis) in a Phase 1b clinical study

Acousia Therapeutics GmbH – along with its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and

Acousia Therapeutics GmbH has been granted CTA (Clinical Trial Authorization) by the German BfArM (Federal Institute for Drugs and Medical Devices) for the first-in-man clinical

The senior management of Acousia Therapeutics GmbH will be discussing the company’s approach to translational development of small molecule drug candidates for the treatment of

Starting November 1, 2020, Jonas Dyhrfjeld-Johnsen will be joining the Acousia Therapeutics management team in the newly established role of chief development officer. Having worked